Viking Therapeutics/VKTX

$68.62

-3.06%
-
1D1W1MYTD1YMAX

About Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on the development of therapies for treatment of metabolic and endocrine disorders. The Company's clinical programs include VK2809, an orally available, small molecule selective thyroid hormone receptor beta agonist for the treatment of lipid and metabolic disorders, which is being evaluated in a Phase II b study for the treatment of biopsy-confirmed non-alcoholic steatohepatitis (NASH) and fibrosis. The Company is developing VK0214, which is also an orally available, tissue and receptor-subtype selective agonist of TRb for X-linked adrenoleukodystrophy (X-ALD), a rare X-linked, inherited neurological disorder characterized by a breakdown in the protective barriers surrounding brain and nerve cells. It is also developing VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors for the treatment of various metabolic disorders.

Ticker

VKTX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Brian Lian

Employees

27

Headquarters

San diego, United States

VKTX Metrics

BasicAdvanced
$7.81B
Market cap
-
P/E ratio
-$0.92
EPS
1.13
Beta
-
Dividend rate
$7.81B
1.12694
$99.41
$8.28
6.39M
19.191
-31.99%
-34.79%
-34.64%
20.364
22.419
-2.11%

What the Analysts think about VKTX

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 10 analysts.
65.84% upside
High $138.00
Low $90.00
$68.62
Current price
$113.80
Average price target

VKTX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-24.6M
9.33%
Profit margin
0%
-

VKTX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 1.32%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.25
-$0.19
-$0.23
-$0.25
-
Expected
-$0.24
-$0.19
-$0.22
-$0.25
-$0.28
Surprise
4.17%
-1.23%
4.98%
-1.32%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Viking Therapeutics stock?

Viking Therapeutics (VKTX) has a market cap of $7.81B as of April 13, 2024.

What is the P/E ratio for Viking Therapeutics stock?

The price to earnings (P/E) ratio for Viking Therapeutics (VKTX) stock is 0 as of April 13, 2024.

Does Viking Therapeutics stock pay dividends?

No, Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders as of April 13, 2024.

When is the next Viking Therapeutics dividend payment date?

Viking Therapeutics (VKTX) stock does not pay dividends to its shareholders.

What is the beta indicator for Viking Therapeutics?

Viking Therapeutics (VKTX) has a beta rating of 1.13. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Viking Therapeutics stock price target?

The target price for Viking Therapeutics (VKTX) stock is $113.8, which is 65.84% above the current price of $68.62. This is an average based on projections from 10 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Viking Therapeutics stock

Buy or sell Viking Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing